Keyphrases
Tumor-infiltrating Lymphocytes
55%
T Cells
49%
Dendritic Cells
45%
Adoptive Cell Therapy
38%
Programmed Death-ligand 1 (PD-L1)
28%
Specific T Cells
26%
Tumor
26%
Metastatic Melanoma
17%
In Cancer
17%
Checkpoint Inhibitors
16%
Melanoma
15%
Cancer Patients
15%
Tumor Antigen
15%
Cancer Cells
12%
Epitope
12%
Immune Modulatory Vaccine
12%
Cancer Immunotherapy
11%
T Cell Response
11%
CD8+ T Cells
11%
Healthy Donors
10%
Cell-based
10%
Cancer Vaccine
9%
Clinical Grade
9%
Ovarian Cancer
9%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
8%
CXCR2
8%
Calreticulin
8%
Inhibitor Resistant
8%
Dendritic Cell Vaccine
8%
Tumor-infiltrating Lymphocyte Therapy
8%
Vaccination
8%
Immune Response
7%
Immunogenicity
7%
Autoreactive T Cells
7%
Breast Cancer Patients
7%
Tumor Fragment
6%
Peripheral Blood
6%
Tumor Microenvironment
6%
Malignant T Cells
6%
Peptide Vaccination
6%
Costimulatory Molecules
6%
Electroporation
6%
Immune Therapy
6%
Cancer Immune Therapy
6%
Clinical Response
5%
Immunogenic Potential
5%
Transforming Growth Factor-β
5%
Cytotoxic T Cells
5%
Thioredoxin-interacting Protein (TXNIP)
5%
Mitochondrial Respiration
5%
Immunology and Microbiology
T Cell
100%
Dendritic Cell
54%
Vaccination Policy
22%
Vaccine Efficacy
21%
Epitope
21%
Programmed Death-Ligand 1
18%
Cytotoxic T-Cell
16%
Tumor-Infiltrating Lymphocytes
15%
Immune Response
14%
Cancer Immunotherapy
13%
Cancer Cell
13%
Tumor Antigen
12%
Cancer Vaccine
11%
Maturation
11%
Immunotherapy
11%
CD8
9%
Cytotoxic T Cell
9%
Cytokine
9%
Regulatory T Cell
8%
Immunogenicity
8%
Immunocompetent Cell
8%
Tumor Cell
7%
Monocyte
7%
T-Helper Cell
6%
Mouse
6%
Genetic Transfection
6%
CTLA-4
6%
Electroporation
6%
Adoptive Immunity
6%
T Cell Receptor
5%
Mitochondrial Respiration
5%
Calreticulin
5%
Chemokine Receptor
5%
Nuclear Reprogramming
5%
Peripheral Blood Mononuclear Cell
5%
Dendritic Cell Vaccine
5%
Medicine and Dentistry
T Cell
52%
Tumor Infiltrating Lymphocyte
47%
Cell Therapy
29%
Neoplasm
28%
Nodular Melanoma
14%
Malignant Neoplasm
14%
Dendritic Cell
14%
Cytotoxic T-Cell
12%
Ovarian Cancer
11%
Immunotherapy
11%
Metastatic Melanoma
10%
Tumor Antigen
8%
Interleukin 8 Receptor, Beta
8%
Breast Cancer
8%
Immune Response
8%
Ex Vivo
7%
CTLA-4
6%
Programmed Death-Ligand 1
6%
In Vitro
6%
Arginase 1
5%
Arginase
5%
Epitope
5%
